• Chemomab Therapeutics will hold a special shareholder meeting on December 4, 2026, to vote on its proposed merger with Scipher Medicine.
• The transaction is expected to close in early 2027, subject to shareholder approval and other closing conditions.
• Before the proposed private placement, existing Chemomab equity holders would own approximately 32% of the combined company; Scipher holders approximately 68%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020800PRIMZONEFULLFEED9867788) on November 02, 2026, and is solely responsible for the information contained therein.